ARTICLE | Clinical News
Gazyva regulatory update
November 16, 2015 8:00 AM UTC
FDA accepted and granted Priority Review to an sBLA from Roche’s Genentech unit for Gazyva obinutuzumab to treat patients with follicular lymphoma who relapsed after or are refractory to a rituximab-c...